IMRN - Immuron FY23 sales jumps by 136% Y/Y to A$$1.80 M
2023-07-05 06:18:31 ET
- Immuron ( NASDAQ: IMRN ) announces 136% Y/Y increase in FY23 sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan and Protectyn to AUD $1.80 M, compared to AUD $765K in FY22.
- FY23 sales of Travelan and Protectyn were AUD $1.16 M in Australia, 478% Y/Y., while sales in US were A$643K, increase of 28% over prior year.
- Travelan sales increased in Australia as overseas travel rebounds. Travelan sales grew in US amid increasing sales in both Passport Health Travel Clinics and distributor sales partially offset by by supply constraints.
- Source: Press Release
For further details see:
Immuron FY23 sales jumps by 136% Y/Y to A$$1.80 M